Head to Head Contrast: Nevro Corp. (NVRO) vs. The Competition
Nevro Corp. (NYSE: NVRO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare Nevro Corp. to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, analyst recommendations, valuation and risk.
Earnings & Valuation
This table compares Nevro Corp. and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Nevro Corp.||$277.91 million||-$22.57 million||-65.86|
|Nevro Corp. Competitors||$827.23 million||$159.49 million||35.82|
Nevro Corp.’s competitors have higher revenue and earnings than Nevro Corp.. Nevro Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current recommendations and price targets for Nevro Corp. and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nevro Corp. Competitors||326||1495||2617||105||2.55|
Nevro Corp. currently has a consensus target price of $102.00, indicating a potential upside of 12.24%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.66%. Given Nevro Corp.’s stronger consensus rating and higher possible upside, analysts clearly believe Nevro Corp. is more favorable than its competitors.
Risk & Volatility
Nevro Corp. has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500. Comparatively, Nevro Corp.’s competitors have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.
This table compares Nevro Corp. and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nevro Corp. Competitors||-128.72%||-37.38%||-10.55%|
Institutional and Insider Ownership
63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 12.1% of Nevro Corp. shares are held by insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Nevro Corp. Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.